16:13 , Feb 20, 2019 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: Transgenics and knockouts; pharmacokinetics/pharmacodynamics Rats expressing human UGT2 or CYP3A gene clusters could be used to predict the PK of drug compounds metabolized by the two enzyme families. Rats engineered to express the entire...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
16:14 , Apr 27, 2018 |  BC Week In Review  |  Company News

UCB buys rights to seizure candidate

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and is eligible for $220 million in milestones. The...
19:52 , Apr 20, 2018 |  Company News  |  Company News

UCB buys rights to seizure candidate

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and is eligible for $220 million in milestones. The...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
19:09 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Paion's remimazolam meets in Phase III trial for procedural sedation

Paion AG (Xetra:PA8) reported data from a Phase III trial in 431 patients undergoing bronchoscopy showing that procedural sedation with remimazolam (CNS 7056, ONO-2745) met the composite primary endpoint vs. both placebo and midazolam of...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

Remimazolam: Phase III started

Paion began a double-blind, U.S. Phase III trial to compare IV remimazolam vs. placebo and open-label midazolam in about 75 high-risk patients undergoing a colonoscopy. Patients will receive 2.5-5 mg initial doses of remimazolam followed...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

Remimazolam: Phase III started

Paion began a double-blind, placebo-controlled, U.S. Phase III trial to compare IV remimazolam vs. midazolam in 460 patients undergoing bronchoscopies. Patients will receive 5 mg remimazolam for induction and 2.5 mg top-ups for maintenance. Paion...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Remimazolam: Phase III started

Paion began a double-blind, placebo-controlled, U.S. Phase III trial to compare IV remimazolam vs. midazolam in about 460 patients undergoing colonoscopy. Patients will receive 5 mg remimazolam for induction and 2.5 mg top-ups for maintenance....